Experimental Therapy Shows Promise in Pancreatic Cancer Clinical Trial
Lombardi Comprehensive Cancer Center at Georgetown UniversityClinicians at Georgetown University’s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda).